Editor’s note: This is a developing news story. Please check back soon for updates.
Aldeyra Therapeutics received FDA fast track designation for ADX-2191 for the treatment of retinitis pigmentosa, according to a press release.
ADX-2191 is an intravitreal formulation of methotrexate that previously received FDA orphan drug designation.
In a phase 2 clinical trial, ADX-2191 helped improve best corrected visual acuity, low-light visual acuity, time to electroretinographic response to light, macular sensitivity to light and dark-adapted peripheral sensitivity to light. It was well tolerated